XBIT 股價走勢圖
XBIT 財務
XBiotech Inc
$2.46
-1.6%
$-0.04
收盤價：May 08, 16:00:00 GMT-4
$2.46
0%
$0
盤後：May 08, 20:00:00 GMT-4
返回
XBiotech Inc (XBIT) 財務
關鍵數據
前收市價
$2.5
開盤價
$2.52
當日範圍
$2.46 - $2.52
52週區間
$2.09 - $3.61
交易量
21.9K
平均成交量
39.4K
股息收益率
--
每股盈餘 (TTM)
-1.49
市值
$75.0M
什麼是 XBIT？
XBiotech, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutic antibodies. The company is headquartered in Austin, Texas and currently employs 85 full-time employees. The company went IPO on 2015-04-15. The firm's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The firm is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. The company has various candidate products, including Natrunix. The company has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.
